Gregoire Berthod
Overview
Explore the profile of Gregoire Berthod including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
247
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klecka M, Rodrigues B, Berthod G, Gobin N
Rev Med Suisse
. 2024 Feb;
20(860):305-310.
PMID: 38323766
The most important modifiable risk factors of renal cell carcinoma are smoking, obesity and hypertension. A biopsy of the renal tumour is not always necessary. It is important in situations...
2.
Wautier C, Gourmaud J, Dong C, Berthod G
Case Rep Oncol
. 2024 Feb;
17(1):191-201.
PMID: 38312748
Introduction: Encorafenib and binimetinib, a combination of BRAF and MEK inhibitors, is a standard of care for patients with advanced BRAFV600-mutant melanoma. This combination is known to have gastrointestinal side...
3.
Barras D, Ghisoni E, Chiffelle J, Orcurto A, Dagher J, Fahr N, et al.
Sci Immunol
. 2024 Feb;
9(92):eadg7995.
PMID: 38306416
Adoptive cell therapy (ACT) using ex vivo-expanded tumor-infiltrating lymphocytes (TILs) can eliminate or shrink metastatic melanoma, but its long-term efficacy remains limited to a fraction of patients. Using longitudinal samples...
4.
Senglet M, Berthod G, Courtes M, Anchisi S, Membrez V, Nay Fellay C
Rev Med Suisse
. 2023 May;
19(827):932-937.
PMID: 37195105
PARP inhibitors (PARPi) have established themselves as a class of essential anti-cancer drugs. They inhibit PARP proteins involved in DNA damage repair. Their anti-tumor action requires a concomitant abnormality in...
5.
Gautron Moura B, Gerard C, Testart N, Caikovski M, Wicky A, Aedo-Lopez V, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612030
Combined ipilimumab and nivolumab significantly improve outcomes in metastatic melanoma patients but bear an important financial impact on the healthcare system. Here, we analyze the treatment costs, focusing on irAE....
6.
Sibon D, Bisig B, Bonnet C, Poullot E, Bachy E, Cavalieri D, et al.
Haematologica
. 2022 Dec;
108(6):1590-1603.
PMID: 36453105
ALK-negative anaplastic large cell lymphoma (ALCL) comprises subgroups harboring rearrangements of DUSP22 (DUSP22- R) or TP63 (TP63-R). Two studies reported 90% and 40% 5-year overall survival (OS) rates in 21...
7.
Aedo-Lopez V, Gerard C, Boughdad S, Gautron Moura B, Berthod G, Digklia A, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267470
To assess the safety and efficacy of ipilimumab plus nivolumab around selective internal radiation therapy (SIRT) in patients with metastatic uveal melanoma (mUM). We present a retrospective, single center study...
8.
Huber A, Latifyan S, Nikolopoulou A, Homicsko K, Berthod G, Michielin O, et al.
Rev Med Suisse
. 2020 May;
16(695):1092-1097.
PMID: 32462837
The standard of care of melanoma patients has evolved at a rapid pace with the advent of immune checkpoint inhibitors and BRAF and MEK inhibitors. ESMO guidelines were revised in...
9.
Simand P, Berthod G, Parmentier L, Anchisi S
Rev Med Suisse
. 2020 May;
16(695):1086-1091.
PMID: 32462836
Dermatologic toxicities appear to be the most prevalent immunotherapy related adverse effects, both with anti-PD-1 and anti-CTLA-4 agents, as well as with the newly developed anti-PD-L1. They occur in more...
10.
Martins F, Schiappacasse L, Levivier M, Tuleasca C, Cuendet M, Aedo-Lopez V, et al.
J Neurooncol
. 2019 Dec;
146(1):181-193.
PMID: 31836957
Background: Evidence pointing to a synergistic effect of stereotactic radiosurgery (SRS) with concurrent immunotherapy or targeted therapy in patients with melanoma brain metastases (BM) is increasing. We aimed to analyze...